Abstract
The growth of U-87 or C6 gliomas co-implanted in nude mice with retroviral producer cells (VPC) expressing the herpes simplex virus-thymidine kinase (HSV-tk) gene is only partially impaired by treatment with ganciclovir (GCV). The effect of GCV is even less evident when C6 and VPC are co-implanted into the rat brain. Furthermore, tumors from C6 cells carrying the HSV-tk gene are not eradicated by GCV, although they remain sensitive to GCV when replated in vitro. These limits of the HSV-tk/GCV system in glioma gene therapy may be due to insufficient gene transfer and/or insufficient delivery of GCV to glioma cells. Combination of HSV-tk and one or more cytokines may improve the antitumor efficacy. Among cytokines, interleukin-4 (IL-4) has already been shown to be active against gliomas. In nude mice, GCV treatment inhibited tumor growth more effectively after co-injection of C6 cells with a mixture of VPC transducing IL-4 and HSV-tk genes than after co-injection with either IL-4 or HSV-tk VPC only. In immunocompetent Sprague-Dawley rats, co-injection of IL-4 VPC and C6 cells was also effective in inhibiting the growth of C6 brain tumors, 38% of the animals surviving for at least 2 months. Furthermore, increased and prolonged antitumor efficacy was obtained by transducing both IL-4 and HSV-tk genes.
Overview summary
We used the herpes simplex virus-thymidine kinase/ganciclovir (HSV-tk/GCV) system to treat C6 or U-87 malignant gliomas implanted in rat brain or in nude mice and found that such treatment is hampered not only by a limited capacity for gene transfer but also by a limited delivery of GCV. These results suggest that other strategies should be used to complement such a system. Our data indicate that by combining the retrovirus-mediated transfer of the interleukin-4 (IL-4) gene to that of the HSV-tk gene a more effective limitation in the growth of malignant gliomas can be obtained in nude mice and that this antitumor effect is stronger and more prolonged in immunocompetent rats.
Get full access to this article
View all access options for this article.
